Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Severe COVID-19
NCT04305106Phase 3Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in COVID-19 pneumonia comparing Bevacizumab with Placebo (2 arms). Primary endpoint: The time from randomization to clinical improvement at 28 days. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04305106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305106.